AB002. Anlotinib as salvage treatment for patients with relapsed and refractory thymic epithelial tumors

BACKGROUND: Optimal pharmaceutical regimen for advanced thymic epithelial tumors (TETs) remains controversial when first-line chemotherapy fails. This retrospective study aims to evaluate the efficacy and safety of anlotinib treatment for patients with relapsed and refractory TETs. METHODS: Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chang-Lu, Zhao, Yi-Zhuo, Zhang, Qin, Zeng, Wan-Qin, Jia, Tian-Ying, Zhu, Lei, Fang, Wen-Tao, Fu, Xiao-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792827/
http://dx.doi.org/10.21037/med-22-ab002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792827/
http://dx.doi.org/10.21037/med-22-ab002

Ejemplares similares